AI assistant
Bio Green Med Solution, Inc. — Director's Dealing 2025
Feb 10, 2025
35092_dirs_2025-02-10_b6192805-17f5-4954-bede-ad935931b822.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2025-02-06
Reporting Person: Lazar David E. (Interim CEO, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-06 | Series D Convertible Preferred Stock | $ | A | 2100000 | Acquired | Common Stock (231000000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series C Convertible Preferred Stock | $ | Common Stock (2650000) | 1000000 | Direct |
Footnotes
F1: On January 2, 2025, David E. Lazar (the "Reporting Person") and Cyclacel Pharmaceuticals, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person agreed to acquire (i) an aggregate of 1,000,000 shares of the Company's Series C Convertible Preferred Stock (the "Series C Preferred Stock") at a price of $1.00 per share and (ii) an aggregate of 2,100,000 shares of the Company's Series D Convertible Preferred Stock (the "Series D Preferred Stock", and together with the Series C Preferred Stock, the "Preferred Stock") at a price of $1.00 per share. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time. The initial closing took place on January 6, 2025, whereby the Reporting Person acquired 1,000,000 shares of Series C Preferred Stock for a total purchase price of $1,000,000.
F2: The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
F3: The Series C Preferred Stock is perpetual and therefore has no expiration date.
F4: At a closing on February 6, 2025, the Reporting Person acquired 2,100,000 shares of Series D Preferred Stock for a total purchase price of $2,100,000. Each share of Series D Preferred Stock is convertible into 110 shares of the Company's Common Stock at any time.
F5: The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
F6: The Series D Preferred Stock is perpetual and therefore has no expiration date.